{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:47:19Z","timestamp":1791542839507,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cgh.2022.02.030","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T21:09:57Z","timestamp":1645218597000},"page":"1456-1479.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Anuraag","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-3409","authenticated-orcid":false,"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.02.030_bib1","article-title":"Review of COVID-19 vaccine subtypes, efficacy and geographical distributions","author":"Francis","year":"2021","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cgh.2022.02.030_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cgh.2022.02.030_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2050640620972602","article-title":"Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Singh","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2022.02.030_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood.2021014232","article-title":"Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients","volume":"139","author":"Maillard","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cgh.2022.02.030_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cgh.2022.02.030_bib6","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib7","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/ibd\/izaa353","article-title":"Hepatitis-B vaccine response in inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"27","author":"Kochhar","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S2468-1253(21)00075-3","article-title":"The impact of SARS-CoV-2 variants on IBD management","volume":"6","author":"Segal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2022.02.030_bib10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2022.02.030_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.cgh.2022.02.030_bib13","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et\u00a0al. Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. JBI; 2020. Available at: https:\/\/synthesismanual.jbi.global. Accessed January 20, 2022.","DOI":"10.46658\/JBIRM-17-06"},{"key":"10.1016\/j.cgh.2022.02.030_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2022.02.030_bib15","doi-asserted-by":"crossref","first-page":"i022","DOI":"10.1093\/ecco-jcc\/jjab232.020","article-title":"OP21 COVID-19 vaccine-induced antibody responses are impaired in inflammatory bowel disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab","volume":"16","author":"Alexander","year":"2022","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.gastro.2021.06.076","article-title":"Collaborators of the Maccabi Institute for Research & Innovation COVID-19 Task Force. BNT162b2 Messenger RNA COVID-19 vaccine effectiveness in patients with inflammatory bowel disease: preliminary real-world data during mass vaccination campaign","volume":"161","author":"Ben-Tov","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14309\/ajg.0000000000001570","article-title":"Humoral immunogenicity of mRNA COVID-19 vaccines among patients with inflammatory bowel disease and healthy control subjects","volume":"117","author":"Caldera","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib18","article-title":"Anti-SARS-CoV-2 vaccination and antibody response in patients with inflammatory bowel disease on immune-modifying therapy: prospective single-tertiary study","author":"Cerna","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib19","first-page":"1327","article-title":"Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-\u03b1 inhibitors","volume":"2","author":"Chen","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.cgh.2022.02.030_bib20","doi-asserted-by":"crossref","first-page":"e1493","DOI":"10.1016\/j.cgh.2021.12.007","article-title":"Impact of inflammatory bowel disease therapies on durability of humoral response to SARS-CoV-2 vaccination","volume":"20","author":"Charilaou","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib21","article-title":"Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease - results of a single-center cohort study in a tertiary hospital in Germany","author":"Classen","year":"2021","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib22","article-title":"Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease","author":"Dailey","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2022.02.030_bib24","doi-asserted-by":"crossref","first-page":"i156","DOI":"10.1093\/ecco-jcc\/jjab232.169","article-title":"P040 Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)","volume":"16","author":"Doherty","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.gastro.2021.10.029","article-title":"REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF\u03b1","volume":"162","author":"Edelman-Klapper","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.12.045","article-title":"Antibody response six months after SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease","author":"Frey","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib27","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000001630","article-title":"Immune response induced by SARS-CoV-2 vaccines in patients with inflammatory bowel disease under biologic therapy","author":"Garrido","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib28","doi-asserted-by":"crossref","first-page":"i586","DOI":"10.1093\/ecco-jcc\/jjab232.806","article-title":"P685 Strong response to SARS-CoV-2 vaccine additional doses among patients with inflammatory bowel diseases","volume":"16","author":"Kappelman","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib29","article-title":"Factors affecting initial humoral immune response to SARS-Cov-2 vaccines among patients with inflammatory bowel diseases","author":"Kappelman","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib30","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.02.030_bib31","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.gastro.2021.12.029","article-title":"Safety and effectiveness of the BNT162B2 MRNA COVID-19 vaccine in a nationwide cohort of patients with inflammatory bowel disease","volume":"162","author":"Khan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib33","doi-asserted-by":"crossref","first-page":"i349","DOI":"10.1093\/ecco-jcc\/jjab232.457","article-title":"P330 Immunity in patients with inflammatory bowel disease on biologic therapy after COVID-19 vaccination","volume":"16","author":"Knezevic","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.gastro.2021.05.030","article-title":"COVID-19 vaccination and inflammatory bowel disease: desired antibody responses, future directions, and a note of caution","volume":"162","author":"Levine","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib35","doi-asserted-by":"crossref","first-page":"e1263","DOI":"10.1016\/j.cgh.2021.12.026","article-title":"COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation","volume":"20","author":"Lev-Tzion","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib36","doi-asserted-by":"crossref","unstructured":"Li D, Xu A, Mengesha E, et\u00a0al. The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders. medRxiv https:\/\/doi.org\/10.1101\/2021.12.08.21267444.","DOI":"10.1101\/2021.12.08.21267444"},{"key":"10.1016\/j.cgh.2022.02.030_bib37","doi-asserted-by":"crossref","unstructured":"Lin S, Kennedy NA, Saifuddin A, et\u00a0al.; Contributors of the CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following 2 SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients. medRxiv https:\/\/doi.org\/10.1101\/2021.11.10.21266168.","DOI":"10.1101\/2021.11.10.21266168"},{"key":"10.1016\/j.cgh.2022.02.030_bib38","doi-asserted-by":"crossref","first-page":"i509","DOI":"10.1093\/ecco-jcc\/jjab232.692","article-title":"P566 Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics","volume":"16","author":"L\u00f3pez Marte","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib39","doi-asserted-by":"crossref","first-page":"i533","DOI":"10.1093\/ecco-jcc\/jjab232.726","article-title":"P600 Serologic response to COVID-19 vaccines in IBD patients: a prospective study","volume":"16","author":"Martin Arranz","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib40","doi-asserted-by":"crossref","first-page":"i525","DOI":"10.1093\/ecco-jcc\/jjab232.714","article-title":"P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with inflammatory bowel disease receiving anti-TNF and thiopurine treatment","volume":"16","author":"Mayorga Ayala","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.7326\/M21-2483","article-title":"Antibody responses after SARS-CoV-2 mRNA vaccination in adults with inflammatory bowel disease","volume":"174","author":"Melmed","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2022.02.030_bib42","doi-asserted-by":"crossref","first-page":"i538","DOI":"10.1093\/ecco-jcc\/jjab232.732","article-title":"P606 Use of TNF-\u03b1-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with inflammatory bowel disease","volume":"16","author":"Otten","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib43","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1053\/j.gastro.2021.08.014","article-title":"Decreased antibody responses to Ad26.COV2.S relative to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease","volume":"161","author":"Pozdnyakova","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib44","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/j.gastro.2021.12.098","article-title":"Serological responses to Sars-Cov-2 vaccination in patients with inflammatory bowel disease: a prospective cohort study","volume":"162","author":"Quan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib45","doi-asserted-by":"crossref","first-page":"i337","DOI":"10.1093\/ecco-jcc\/jjab232.440","article-title":"REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. P313 Within, 6 months from COVID-19 BNT162b2 vaccine patients with inflammatory bowel diseases treated with anti-TNF\u03b1 have significantly lower serologic responses","volume":"16","author":"Rabinowitz","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib46","article-title":"T\u00a0cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease","author":"Reuken","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib47","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Martin\u00f3 E, Medina-Prieto R, Santana-Bagur J, et\u00a0al. Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics and\/or immunomodulators. medRxiv https:\/\/doi.org\/10.1101\/2021.09.11.21263211.","DOI":"10.1101\/2021.09.11.21263211"},{"key":"10.1016\/j.cgh.2022.02.030_bib48","doi-asserted-by":"crossref","unstructured":"Schell TL, Knutson KL, Saha S, et\u00a0al. Humoral immunogenicity of three COVID-19 mRNA vaccine doses in patients with inflammatory bowel disease. medRxiv https:\/\/doi.org\/10.1101\/2021.12.22.21268217.","DOI":"10.1101\/2021.12.22.21268217"},{"key":"10.1016\/j.cgh.2022.02.030_bib49","first-page":"5362","article-title":"Immunogenicity of BNT162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study","volume":"10","author":"Shehab","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2022.02.030_bib50","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/vaccines9121471","article-title":"Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies","volume":"9","author":"Shehab","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cgh.2022.02.030_bib51","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib52","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ibd\/izab194","article-title":"Seroconversion following SARS-CoV-2 infection or vaccination in pediatric IBD patients","volume":"27","author":"Spencer","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib53","doi-asserted-by":"crossref","first-page":"i283","DOI":"10.1093\/ecco-jcc\/jjab232.362","article-title":"P235 The natural history of COVID-19 in vaccinated inflammatory bowel disease patients","volume":"16","author":"Viazis","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/biomedicines10010171","article-title":"Humoral immune response in IBD patients three and six months after vaccination with the SARS-CoV-2 mRNA vaccines mRNA-1273 and BNT162b2","volume":"10","author":"Vollenberg","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cgh.2022.02.030_bib55","doi-asserted-by":"crossref","first-page":"i074","DOI":"10.1093\/ecco-jcc\/jjab232.063","article-title":"J-COMBAT trial group. DOP24 Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in inflammatory bowel disease patients: interim analyses of the J-COMBAT trial","volume":"16","author":"Watanabe","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib56","doi-asserted-by":"crossref","unstructured":"Wagner A, Garner-Spitzer E, Sch\u00f6tta A, et\u00a0al. Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination. medRxiv https:\/\/doi.org\/10.1101\/2021.12.13.21267603.","DOI":"10.1101\/2021.12.13.21267603"},{"key":"10.1016\/j.cgh.2022.02.030_bib57","article-title":"Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID","author":"Weaver","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib59","doi-asserted-by":"crossref","first-page":"i581","DOI":"10.1093\/ecco-jcc\/jjab232.798","article-title":"P677 Patients with inflammatory bowel diseases on anti-TNF treatment have impaired antibody production after Anti-SARS-CoV-2 vaccination: results from a Panhellenic registry","volume":"16","author":"Zacharopoulou","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib60","doi-asserted-by":"crossref","first-page":"i190","DOI":"10.1093\/ecco-jcc\/jjab232.221","article-title":"P092 Humoral and T cell responses to COVID-19 vaccination in IBD","volume":"16","author":"Zhang","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib61","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2468-1253(21)00374-5","article-title":"British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease","volume":"6","author":"Alexander","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S2468-1253(21)00347-2","article-title":"SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy","volume":"6","author":"Selim","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib63","article-title":"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study","author":"Alexander","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/v14010079","article-title":"SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against omicron","volume":"14","author":"Ahmed","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cgh.2022.02.030_bib65","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2022.02.030_bib66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.02.030_bib67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","volume":"185","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2022.02.030_bib68","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.14309\/ajg.0000000000001342","article-title":"Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease","volume":"116","author":"Botwin","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14309\/ajg.0000000000001570","article-title":"Humoral immunogenicity of mRNA COVID-19 vaccines among patients with inflammatory bowel disease and healthy controls","volume":"117","author":"Caldera","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib70","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1053\/j.gastro.2021.12.211","article-title":"Anti-Sars-Cov-2 vaccination and antibody response in patients with inflammatory bowel disease on immune-modifying therapy. prospective single tertiary center study on 602 IBD patients","volume":"162","author":"Cerna","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib71","doi-asserted-by":"crossref","first-page":"i425","DOI":"10.1093\/ecco-jcc\/jjab232.571","article-title":"P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort","volume":"16","author":"Farkas","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib72","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000776632.28228.ab","article-title":"S775 Seroprevalence of COVID-19 in patients with inflammatory bowel disease under biologic treatment","volume":"116","author":"Garrido","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib73","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000776752.12450.81","article-title":"S805 SARS-CoV-2 vaccine antibody response in patients with IBD","volume":"116","author":"Garza","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib74","doi-asserted-by":"crossref","unstructured":"Hadi YB, Thakkar S, Shah-Khan SM, et\u00a0al. COVID-19 Vaccination is safe and effective in patients with inflammatory bowel disease: analysis of a large multi-institutional research network in the United States. Gastroenterology. 202;161:1336\u20131339.e3.","DOI":"10.1053\/j.gastro.2021.06.014"},{"key":"10.1016\/j.cgh.2022.02.030_bib75","doi-asserted-by":"crossref","first-page":"i406","DOI":"10.1093\/ecco-jcc\/jjab232.544","article-title":"P417 Seroconversion after COVID-19 vaccination in inflammatory bowel disease patients","volume":"16","author":"Horvath","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib76","doi-asserted-by":"crossref","first-page":"i537","DOI":"10.1093\/ecco-jcc\/jjab232.731","article-title":"P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study","volume":"16","author":"J\u00f8rgensen","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib77","doi-asserted-by":"crossref","first-page":"i586","DOI":"10.1093\/ecco-jcc\/jjab232.806","article-title":"P685 Strong response to SARS-CoV-2 vaccine additional doses among patients with inflammatory bowel diseases","volume":"16","author":"Kappelman","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib78","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2021.06.016","article-title":"Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease","volume":"161","author":"Kappelman","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.030_bib79","doi-asserted-by":"crossref","first-page":"i291","DOI":"10.1093\/ecco-jcc\/jjab232.371","article-title":"P244 COVID-19 vaccine does not increase the likelihood of disease exacerbation in IBD: results from a population-based study","volume":"16","author":"Lev Zion","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib80","doi-asserted-by":"crossref","first-page":"i365","DOI":"10.1093\/ecco-jcc\/jjab232.481","article-title":"P354 Immunological response to vaccination against SARS-COV-2 infection in inflammatory bowel disease patients under immunosuppressive therapy: should we prioritize an additional booster injection?","volume":"16","author":"Macedo Silva","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib81","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3390\/v13112143","article-title":"Impairment of CD4+ T and memory B cell responses but normal memory CD8+T-cell activation on Crohn\u2019s disease after COVID-19 vaccination: a twin case","volume":"13","author":"Melga\u00e7o","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cgh.2022.02.030_bib82","doi-asserted-by":"crossref","first-page":"i334","DOI":"10.1093\/ecco-jcc\/jjab232.434","article-title":"P307 The effect of COVID-19 infection and vaccination in patients with inflammatory bowel disease and irritable bowel syndrome","volume":"16","author":"Sciberras","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.02.030_bib83","article-title":"Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy","author":"Shire","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.02.030_bib84","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/ibd\/izab094","article-title":"COVID-19 vaccination in patients with inflammatory bowel disease and history of reaction to injectable therapies","volume":"27","author":"Squire","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.02.030_bib85","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cgh.2022.02.030_bib86","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.14309\/01.ajg.0000798832.85361.7a","article-title":"P058 Impact of inflammatory bowel disease treatment and risk of Covid-19 infection after full immunization: a nationwide analysis","volume":"116","author":"Tomanguillo Chumbe","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.030_bib87","doi-asserted-by":"crossref","first-page":"i079","DOI":"10.1093\/ecco-jcc\/jjab232.066","article-title":"T2B! immunity against SARS-CoV-2 study group. DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study","volume":"16","author":"Volkers","year":"2022","journal-title":"J\u00a0Crohns Colitis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:38:05Z","timestamp":1761543485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1542356522001860"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.02.030","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}